April 12, 2022
Ocugen’s phase 2/3 Study of COVAXIN put on hold
FDA has placed on clinical hold Ocugen’s phase 2/3 study for COVAXIN.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Ocugen
February 23, 2022
Ocugen, Inc. Announces Pricing of $53.5 Million Public Offering of Common Stock
MALVERN, Pa., Feb. 22, 2022 (GLOBE NEWSWIRE) — Ocugen, Inc. (Nasdaq: OCGN), a clinical-stage biopharmaceutical company focused on discovering, developing,…